Intervention not reported
Within ± 0.50 D of target refraction at 12 months post treatment · adult participants (≥ 18 years) with myopia
The intervention showed no clear difference in within ± 0.50 D of target refraction at 12 months post treatment (low certainty).
1 finding from 1 review
RR 0.93 [0.84, 1.03]
Studies not reported
Low
Intervention not reported
Loss of 1 or more lines of BSCVA at 12 months post treatment · adult participants (≥ 18 years) with myopia
It is very uncertain whether the intervention changes loss of 1 or more lines of BSCVA at 12 months post treatment (very low certainty).
1 finding from 1 review
RR 3 [0.13, 71.96]
Studies not reported
Very low
Intervention not reported
Mean spherical equivalent at 12 months post treatment · adult participants (≥ 18 years) with myopia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Participants cured or improved · Adults with overactive bladder (OAB)
Electrical stimulation probably leads to higher participants cured or improved compared with placebo or sham treatment (moderate certainty).
1 finding from 1 review
Participants with improvement in urgency urinary incontinence · Adults with overactive bladder (OAB)
Electrical stimulation showed no clear difference in participants with improvement in urgency urinary incontinence compared with placebo or sham treatment (low certainty).
1 finding from 1 review
OAB‐related quality of life · Adults with overactive bladder (OAB)
1 finding from 1 review
Adverse effects · Adults with overactive bladder (OAB)
Electrical stimulation showed no clear difference in adverse effects compared with placebo or sham treatment (low certainty).
1 finding from 1 review
Intervention not reported
Colonic transit rate (geometric centre of radioactive substance). Unit indicates position along with intestinal tract. Scale from: 1 (small intestine) to 5 (rectosigmoid area). · children with chronic constipation
1 finding from 1 review
Intervention not reported
Idoxuridine (B) versus inactive control (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Low
Intervention not reported
Interferon (B) versus inactive control (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Very low
Intervention not reported
Vidarabine (B) versus inactive control (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Low
Condition‐specific quality of life ICIQ Overactive Bladder Symptoms Quality of Life. Scale from: 25 to 160. Better quality of life indicated by lower values. · adults with urinary incontinence
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of active tuberculosis · People with latent tuberculosis
1 finding from 1 review
Disease‐specific quality of life · Adults with overactive bladder (OAB)
Anticholinergics showed no clear difference in mean change from baseline in condition‐specific quality of lifeScale… compared with placebo (low certainty).
1 finding from 1 review
Perception of improvement or cure · Adults with overactive bladder (OAB)
Anticholinergics probably leads to higher patient perception of cure or improvement compared with placebo (moderate certainty).
1 finding from 1 review
Number of urgency episodes per 24 hours: immediately after treatment · Adults with overactive bladder (OAB)
Anticholinergics showed no clear difference in mean number of urgency episodes per 24 hours compared with placebo (moderate certainty).
1 finding from 1 review